RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/24825332/ below:

Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples

Comparative Study

doi: 10.1097/OLQ.0000000000000125. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples

Affiliations

Affiliation

¹ From the *St Joseph's Healthcare, Hamilton, Ontario, Canada; †Juravinski Hospital, Hamilton, Ontario, Canada; ‡McMaster University, Hamilton, Ontario, Canada; and §Hologic/Gen-Probe, San Diego, CA.

PMID: 24825332
DOI: 10.1097/OLQ.0000000000000125

Item in Clipboard

Comparative Study

Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples

Max Chernesky et al. Sex Transm Dis. 2014 Jun.

doi: 10.1097/OLQ.0000000000000125. Affiliation

¹ From the *St Joseph's Healthcare, Hamilton, Ontario, Canada; †Juravinski Hospital, Hamilton, Ontario, Canada; ‡McMaster University, Hamilton, Ontario, Canada; and §Hologic/Gen-Probe, San Diego, CA.

PMID: 24825332
DOI: 10.1097/OLQ.0000000000000125

Item in Clipboard

Abstract

Background: An APTIMA specimen collection and transportation (SCT) kit was developed by Hologic/Gen-Probe.

Objectives: To compare cervical SCT samples to PreservCyt and SurePath samples and self-collected vaginal samples to physician-collected vaginal and cervical SCT samples. To determine ease and comfort of self-collection with the kit.

Study design: Each woman (n = 580) self-collected a vaginal SCT, then filled out a questionnaire (n = 563) to determine ease and comfort of self-collection. Colposcopy physicians collected a vaginal SCT and cervical PreservCyt, SCT, and SurePath samples. Samples were tested by APTIMA HPV (AHPV) assay.

Results: Agreement between testing of cervical SCT and PreservCyt was 91.1% (κ = 0.82), and that of SurePath samples was 86.7% (κ = 0.72). Agreement of self-collected vaginal SCT to physician-collected SCT was 84.7% (κ = 0.68), and that of self-collected vaginal to cervical SCT was 82.0% (κ = 0.63). For 30 patients with CIN2+, AHPV testing of cervical SCT was 100% sensitive and 59.8% specific compared with PreservCyt (96.6% and 66.2%) and SurePath (93.3% and 70.9%). Vaginal SCT sensitivity was 86.7% for self-collection and 80.0% for physician collection. Most patients found that vaginal self-collection was easy, 5.3% reported some difficulty, and 87.6% expressed no discomfort.

Conclusions: Cervical samples collected with the new SCT kit compared well to traditional liquid-based samples tested by AHPV. Although there was good agreement between self-collected and physician-collected samples with the SCT, in a limited number of 30 women, vaginal sampling identified fewer with CIN2+ precancerous cervical lesions than cervical SCT sampling. Comfort, ease of use, and detection of high-risk HPV demonstrated that the kit could be used for cervical and vaginal sampling.

PubMed Disclaimer